Blue Jet Healthcare Valuation

Is BLUEJET undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BLUEJET when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BLUEJET (₹527.25) is trading above our estimate of fair value (₹199.29)

Significantly Below Fair Value: BLUEJET is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLUEJET?

Key metric: As BLUEJET is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BLUEJET. This is calculated by dividing BLUEJET's market cap by their current earnings.
What is BLUEJET's PE Ratio?
PE Ratio	54.5x
Earnings	₹1.68b
Market Cap	₹91.46b

BLUEJET key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	12.2x
Enterprise Value/EBITDA	40x
PEG Ratio	2.3x

Price to Earnings Ratio vs Peers

How does BLUEJET's PE Ratio compare to its peers?

The above table shows the PE ratio for BLUEJET vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	73.1x
500126 Procter & Gamble Health	39.1x	11.3%	₹85.1b
AMIORG Ami Organics	92.2x	42.1%	₹85.9b
531599 FDC	24.9x	n/a	₹78.8b
AETHER Aether Industries	136.3x	44.8%	₹110.1b
BLUEJET Blue Jet Healthcare	54.5x	24.1%	₹91.5b

Price-To-Earnings vs Peers: BLUEJET is good value based on its Price-To-Earnings Ratio (54.5x) compared to the peer average (73.1x).

Price to Earnings Ratio vs Industry

How does BLUEJET's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$71.82m
524652 Ind-Swift	2x	n/a	US$13.29m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: BLUEJET is expensive based on its Price-To-Earnings Ratio (54.5x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is BLUEJET's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLUEJET PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	54.5x
Fair PE Ratio	40x

Price-To-Earnings vs Fair Ratio: BLUEJET is expensive based on its Price-To-Earnings Ratio (54.5x) compared to the estimated Fair Price-To-Earnings Ratio (40x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BLUEJET forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	₹527.25	₹525.00 -0.4%	14.0%	₹600.00	₹425.00	n/a	3
Nov ’25	₹479.20	₹521.67 +8.9%	13.9%	₹600.00	₹425.00	n/a	3
Oct ’25	₹517.80	₹521.67 +0.7%	13.9%	₹600.00	₹425.00	n/a	3
Sep ’25	₹488.85	₹523.33 +7.1%	14.0%	₹600.00	₹425.00	n/a	3
Aug ’25	₹499.10	₹406.67 -18.5%	8.7%	₹445.00	₹360.00	n/a	3
Jul ’25	₹417.75	₹406.67 -2.7%	8.7%	₹445.00	₹360.00	n/a	3
Jun ’25	₹382.30	₹406.67 +6.4%	8.7%	₹445.00	₹360.00	n/a	3
May ’25	₹387.80	₹430.00 +10.9%	4.7%	₹450.00	₹410.00	n/a	2
Apr ’25	₹391.40	₹430.00 +9.9%	4.7%	₹450.00	₹410.00	n/a	2

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

11.6%

27.4%

Caplin Point Laboratories

₹147.7b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,942.80

-0.4%

58.1%

Venus Remedies

₹4.0b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹298.65

-1.3%

-16.9%